Morpholine-4-sulfonyl chloride → HCID 178527581, compound
Reaction equation
Cl.Cl.Cl.[O:4]1[C:8]2[CH:9]=[CH:10][CH:11]=[C:12]([N:13]3[CH2:18][CH2:17][N:16]([CH2:19][CH2:20][C@H:21]4[CH2:26][CH2:25][C@H:24]([NH2:27])[CH2:23][CH2:22]4)[CH2:15][CH2:14]3)[C:7]=2[O:6][CH2:5]1.[N:28]1([S:34](Cl)(=[O:36])=[O:35])[CH2:33][CH2:32][O:31][CH2:30][CH2:29]1>>[O:4]1[C:8]2[CH:9]=[CH:10][CH:11]=[C:12]([N:13]3[CH2:18][CH2:17][N:16]([CH2:19][CH2:20][C@H:21]4[CH2:26][CH2:25][C@H:24]([NH:27][S:34]([N:28]5[CH2:33][CH2:32][O:31][CH2:30][CH2:29]5)(=[O:36])=[O:35])[CH2:23][CH2:22]4)[CH2:15][CH2:14]3)[C:7]=2[O:6][CH2:5]1Participants
3
Procedure
The title compound, white solid (24.6 mg, 60.2%), MS (ISP) m/z=481.2 [(M+H)+], was prepared in accordance with the general method of example 76 from N-trans-4-[2-(4-Benzo[1,3]dioxol-4-yl-piperazin-1-yl)-ethyl]-cyclohexylamine hydrochloride (Intermediate A) (30 mg, 81.5 μmol) and morpholine-4-sulfonyl chloride.
Sources & evidence
- ORD record
- ord-1865b4bf8d614c15b2acb0d24c84e8ca
- Source dataset
- uspto-grants-2014_05
- Patent number
- US08722683B2
Reaction notes
Loading…